8 citations
,
July 2003 in “Journal of the American Geriatrics Society” Venlafaxine may cause paranoid delusions in some patients.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
16 citations
,
October 2018 in “BMC Complementary and Alternative Medicine” Crataeva nurvala leaves may help reduce anxiety and improve sleep.
2 citations
,
September 2014 in “International Journal of Dermatology” Sodium valproate can worsen psoriasis-like skin conditions.
3 citations
,
August 2023 in “The Journal of Pediatrics” Sodium valproate can rarely cause skin darkening, which may improve after stopping the drug.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
August 2008 in “European Neuropsychopharmacology” RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
26 citations
,
September 2014 in “Neuroscience Letters” Metformin protects hair cells in lab tests but not in live animals.
April 2016 in “Journal of The American Academy of Dermatology” Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.
28 citations
,
September 2002 in “The Journal of Comparative Neurology” Presynaptic inhibition of certain nerve fibers in cats is mainly controlled by GABA and glycine.
5 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce tic severity in male Tourette syndrome patients.
August 2023 in “Journal of The American Academy of Dermatology” Valproic acid, a common antiepileptic medication, can cause reversible hair loss in patients.
6 citations
,
January 2012 in “Annals of Indian Academy of Neurology” Women with epilepsy on certain medications might gain weight and have higher thyroid-stimulating hormone levels, but not more polycystic ovarian syndrome.
January 2024 in “Indian Journal of Psychiatry” Precision neuromodulation may improve schizophrenia symptoms.
15 citations
,
December 2016 in “Advanced Pharmaceutical Bulletin” The new cream with N-acetyl glucosamine didn't change skin color after 8 weeks.
July 2025 in “Reactions Weekly” 13 citations
,
October 2023 in “Pharmaceutics” The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.
December 2023 in “Frontiers in pharmacology” Progesterone initially worsens but later reduces neuropathic pain in mice, through different mechanisms.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
10 citations
,
October 2018 in “Journal of molecular and cellular cardiology/Journal of Molecular and Cellular Cardiology” The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.
1 citations
,
September 2007 in “European journal of paediatric neurology” Low dose valproic acid treatment caused hair loss in a young patient.
Neuropeptides affect hair growth and could be used to control it.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
19 citations
,
June 2013 in “Journal of Neuroendocrinology” Neurosteroids may help prevent seizures and slow epilepsy progression.
3 citations
,
October 2023 in “Journal of Pain” Certain proteins might predict surgical success in trigeminal neuralgia treatment.
3 citations
,
January 2025 in “Scientific Reports” Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.